[
    [
        "1. Researchers have found that they produce an antibody that attacks the malaria-causing parasite.",
        "The researchers found that they produce an antibody that attacks the malaria-causing parasite.",
        "The study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.",
        "US researchers have found that they produce an antibody that attacks the malaria-causing parasite.",
        "The passage is about a new vaccine that is being developed to fight malaria. The vaccine is called RTS,S and it is being developed by GlaxoSmithKline. The vaccine has been shown to reduce the number of malaria cases in young children and infants by almost half. The passage also",
        "The US researchers have found that they produce an antibody that attacks the malaria-causing parasite.",
        "The passage is about the US researchers who have found that they produce an antibody that attacks the malaria-causing parasite. The team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.",
        "",
        "US researchers have found that they produce an antibody that attacks the malaria-causing parasite.",
        "1. The study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives."
    ],
    [
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\n1. Researchers have found that they produce an antibody that attacks the malaria-causing parasite.\n2. Injecting a form of this antibody into mice protected the animals from the disease.\n3. The team, which published its results in the journal Science, said trials in",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\nThe researchers found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\nThe passage is about a new vaccine that is being developed to fight malaria. The vaccine is called RTS,S and it is being developed by GlaxoSmithKline. The vaccine has been shown to reduce the number of malaria cases in young children and infants by almost half. The passage also",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\nThe US researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\nThe passage is about the US researchers who have found that they produce an antibody that attacks the malaria-causing parasite. The team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\n\nThe passage is",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\n\n1. The researchers have found that they produce an antibody that attacks the malaria-causing parasite.\n2. The team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\n3. The study",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed",
        "Write a short summary for the following passage:\nUS researchers have found that they produce an antibody that attacks the malaria-causing parasite.\nInjecting a form of this antibody into mice protected the animals from the disease.\nThe team, which published its results in the journal Science, said trials in primates and humans were now needed to fully assess the vaccine's promise.\nProf Jake Kurtis, director of the Center for International Health Research at Rhode Island Hospital, Brown University School of Medicine, said: \"I think there's fairly compelling evidence that this is a bona fide vaccine candidate.\n\"However, it's an incredibly difficult parasite to attack. It's had millions of years of evolution to co-opt and adapt to our immune responses - it really is a formidable enemy.\"\nTrapped inside\nThe study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\nA small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area where the disease was rife.\n\"There are some individuals who become resistant and there are some individuals who do not become resistant,\" explained Prof Kurtis.\n\"We asked what were the specific antibodies expressed by resistant children that were not expressed by susceptible children.\"\nThe team found that an antibody produced by the immune children hits the malaria parasite at a key stage in its life-cycle.\nIt traps the tiny organism in red blood cells, preventing it from bursting out and spreading throughout the body.\nTests, carried out in small groups of mice, suggest this antibody could act as a potential vaccine.\nProf Kurtis said: \"The survival rate was over two-fold longer if the mice were vaccinated compared with unvaccinated -  and the parasitemia  (the number of parasites in the blood) were up to four-fold lower in the vaccinated mice.\"\nThe team said it was encouraged by the results, but stressed more research was required.\nProf Kurtis said: \"I am cautious. I've seen nothing so far in our data that would cause us to lose enthusiasm. However, it still needs to get through a monkey study and the next phase of human trials.\"\nThis latest study is one of many avenues being explored in the race to find a malaria vaccine.\nThe most advanced is the RTS,S vaccine, developed by GlaxoSmithKline.  The drug company is seeking regulatory approval after Phase III clinical trials showed that the drug almost halved the number of malaria cases in young children and reduced by about 25% the number of malaria cases in infants.\nCommenting on the research, Dr Ashley Birkett, director of the PATH Malaria Vaccine Initiative, said: \"The identification of new targets on malaria parasites to support malaria vaccine development is a necessary and important endeavour.\n\"While these initial results are promising with respect to prevention of severe malaria, a lot more data would be needed before this could be considered a leading vaccine approach - either alone or in combination with other antigens.\"\nThe most recent figures from the World Health Organization suggest the disease killed more than 600,000 people in 2012, with 90% of these deaths occurring in sub-Saharan Africa.\nFollow Rebecca on Twitter\nSummary:\n1. The study began with a group of 1,000 children in Tanzania, who had regular blood samples taken in the first years of their lives.\n2. A small number of these children - 6% - developed a naturally acquired immunity to malaria, despite living in an area"
    ],
    [
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        0.0,
        1.0,
        0.0,
        0.0
    ],
    [
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.04333633929491043,
            0.0,
            0.0,
            0.0,
            0.07682193070650101,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.15680064260959625,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            1.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ]
    ],
    [
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -3.138763904571533,
            -Infinity,
            -Infinity,
            -Infinity,
            -2.566265106201172,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -1.8527799844741821,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ],
        [
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            0.0,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity,
            -Infinity
        ]
    ],
    759
]